Durable Response to Combined Osimertinib and Pralsetinib Treatment for Osimertinib Resistance Due to Novel Intergenic ANK3-RET Fusion in EGFR-Mutated Non-Small-Cell Lung Cancer

JCO Precis Oncol. 2022 Jul:6:e2200040. doi: 10.1200/PO.22.00040.

Authors

Edyta M Urbanska¹, Jens B Sørensen¹, Linea C Melchior², Junia C Costa³, Eric Santoni-Rugiu^{2

4}

Affiliations

¹ Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
² Department of Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
³ Department of Radiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
⁴ Biotech Research & Innovation Center (BRIC), University of Copenhagen, Copenhagen, Denmark.

No abstract available

MeSH terms

Acrylamides
Aniline Compounds
Ankyrins
Carcinoma, Non-Small-Cell Lung* / drug therapy
ErbB Receptors / genetics
Humans
Indoles
Lung Neoplasms* / drug therapy
Proto-Oncogene Proteins c-ret
Pyrazoles
Pyridines
Pyrimidines

Substances

ANK3 protein, human
Acrylamides
Aniline Compounds
Ankyrins
Indoles
Pyrazoles
Pyridines
Pyrimidines
pralsetinib
osimertinib
EGFR protein, human
ErbB Receptors
Proto-Oncogene Proteins c-ret
RET protein, human